Insider · CIK 0001753185
Johan Wedell-Wedellsborg
Files at YMAB (Y-mAbs Therapeutics, Inc.). First filing -, latest -.
Johan Wedell-Wedellsborg files SEC Form 4 as director and 10% owner at YMAB (Y-mAbs Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Johan Wedell-Wedellsborg has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stockindirect: By WG Biotech ApS | -4,559,233 | $8.60 | $39M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -36,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -32,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -13,950 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,545 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -33,450 | - | - | 0 | Sep 18, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Common Stock | +25,080 | $0.00 | $0 | 30,905 | Jul 2, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +33,450 | $0.00 | $0 | 33,450 | Jul 2, 2025 |
Questions about Johan Wedell-Wedellsborg
Answered from the filings on this page, as of the latest one.
Is Johan Wedell-Wedellsborg buying or selling?
Johan Wedell-Wedellsborg has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Johan Wedell-Wedellsborg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Johan Wedell-Wedellsborg has 0.
Where does Johan Wedell-Wedellsborg file Form 4?
Johan Wedell-Wedellsborg has filed Form 4 at YMAB (Y-mAbs Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.